Effects of a pharmaceutical care intervention on clinical outcomes and patient adherence in coronary heart disease: the MIMeRiC randomized controlled trial

Malin Johansson Östbring, Tommy Eriksson, Göran Petersson, Lina Hellström, Malin Johansson Östbring, Tommy Eriksson, Göran Petersson, Lina Hellström

Abstract

Background: In the treatment of coronary heart disease, secondary prevention goals are still often unmet and poor adherence to prescribed drugs has been suggested as one of the reasons. We aimed to investigate whether pharmaceutical care by a pharmacist at the cardiology clinic trained in motivational interviewing improves clinical outcomes and patient adherence.

Methods: This was a prospective, randomized, controlled, outcomes-blinded trial designed to compare pharmaceutical care follow-up with standard care. After standard follow-up at the cardiology clinic, patients in the intervention group were seen by a clinical pharmacist two to five times as required over seven months. Pharmacists were trained to use motivational interviewing in the consultations and they tailored their support to each patient's clinical needs and beliefs about medicines. The primary study end-point was the proportion of patients who reached the treatment goal for low-density lipoprotein cholesterol by 12 months after discharge. The key secondary outcome was patient adherence to lipid-lowering therapy at 15 months after discharge, and other secondary outcomes were the effects on patient adherence to other preventive drugs, systolic blood pressure, disease-specific quality of life, and healthcare use.

Results: 316 patients were included. The proportion of patients who reached the target for low-density lipoprotein cholesterol were 37.0% in the intervention group and 44.2% in the control group (P = .263). More intervention than control patients were adherent to cholesterol-lowering drugs (88 vs 77%; P = .033) and aspirin (97 vs 91%; P = .036) but not to beta-blocking agents or renin-angiotensin-aldosterone system inhibitors.

Conclusions: Our intervention had no positive effects on risk factors for CHD, but it increased patient adherence. Further investigation of the intervention process is needed to explore the difference in results between patient adherence and medication effects. Longer follow-up of healthcare use and mortality will determine if the increased adherence per se eventually will have a meaningful effect on patient health.

Trial registration: ClinicalTrials.gov NCT02102503, 03/04/2014 retrospectively registered.

Keywords: Coronary heart disease; Low-density lipoprotein cholesterol; Medication adherence; Medication review; Medicine management; Motivational interviewing; Pharmaceutical care; Randomized controlled trial; Secondary prevention.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2021. The Author(s).

Figures

Fig. 1
Fig. 1
Study flowchart. For those excluded, (i) indicates cognitive impairment or any other condition making interviews or phone calls difficult; (ii) indicates nonparticipation in the standard follow-up at the out-patient clinic; and (iii) indicates prior participation in this study
Fig. 2
Fig. 2
The proportion of patients who refilled their prescription for cholesterol-lowering (CL) drugs, and the proportion of patients who both refilled their prescription and reported adherence to their drug regimen

References

    1. Roth GA, Forouzanfar MH, Moran AE, Barber R, Nguyen G, Feigin VL, et al. Demographic and epidemiologic drivers of global cardiovascular mortality. N Engl J Med. 2015;372(14):1333–1341. doi: 10.1056/NEJMoa1406656.
    1. Bhatnagar P, Wickramasinghe K, Wilkins E, Townsend N. Trends in the epidemiology of cardiovascular disease in the UK. Heart. 2016;102:1945–1952. doi: 10.1136/heartjnl-2016-309573.
    1. Socialstyrelsen. Myocardial Infarctions in Sweden 1994–2014. National Board of Health and Welfare; 2015.
    1. Kotseva K, De Bacquer D, Jennings C, Gyberg V, De Backer G, Ryden L, et al. Time trends in lifestyle, risk factor control, and use of evidence-based medications in patients with coronary heart disease in Europe: results from 3 EUROASPIRE surveys, 1999–2013. Glob Heart. 2017;12(4):315–22 e3. doi: 10.1016/j.gheart.2015.11.003.
    1. Libungan B, Stensdotter L, Hjalmarson A, From Attebring M, Lindqvist J, Back M, et al. Secondary prevention in coronary artery disease. Achieved goals and possibilities for improvements. Int J Cardiol. 2012;161(1):18–24. doi: 10.1016/j.ijcard.2011.04.025.
    1. Hambraeus K, Lindhagen L, Tyden P, Lindahl B, Lagerqvist B. Target-attainment rates of low-density lipoprotein cholesterol using lipid-lowering drugs one year after acute myocardial infarction in sweden. Am J Cardiol. 2014;113(1):17–22. doi: 10.1016/j.amjcard.2013.09.007.
    1. Kramer JM, Hammill B, Anstrom KJ, Fetterolf D, Snyder R, Charde JP, et al. National evaluation of adherence to beta-blocker therapy for 1 year after acute myocardial infarction in patients with commercial health insurance. Am Heart J. 2006;152(3):454 e1–454 e8. doi: 10.1016/j.ahj.2006.02.030.
    1. Ho PM, Magid DJ, Shetterly SM, Olson KL, Maddox TM, Peterson PN, et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J. 2008;155(4):772–779. doi: 10.1016/j.ahj.2007.12.011.
    1. Rodriguez F, Maron DJ, Knowles JW, Virani SS, Lin S, Heidenreich PA. Association of statin adherence with mortality in patients with atherosclerotic cardiovascular disease. JAMA Cardiol. 2019;4(3):206–213. doi: 10.1001/jamacardio.2018.4936.
    1. Huber CA, Meyer MR, Steffel J, Blozik E, Reich O, Rosemann T. Post-myocardial infarction (MI) care: medication adherence for secondary prevention after MI in a large real-world population. Clin Ther. 2019;41(1):107–117. doi: 10.1016/j.clinthera.2018.11.012.
    1. Lauffenburger JC, Isaac T, Bhattacharya R, Sequist TD, Gopalakrishnan C, Choudhry NK. Prevalence and impact of having multiple barriers to medication adherence in nonadherent patients with poorly controlled cardiometabolic disease. Am J Cardiol. 2020;125(3):376–382. doi: 10.1016/j.amjcard.2019.10.043.
    1. Horne R, Weinman J. Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res. 1999;47(6):555–567. doi: 10.1016/S0022-3999(99)00057-4.
    1. Horne R, Chapman SC, Parham R, Freemantle N, Forbes A, Cooper V. Understanding patients' adherence-related beliefs about medicines prescribed for long-term conditions: a meta-analytic review of the Necessity-Concerns Framework. PLoS ONE. 2013;8(12):e80633. doi: 10.1371/journal.pone.0080633.
    1. Unni E, Shiyanbola OO, Farris KB. Change in medication adherence and beliefs in medicines over time in older adults. Global J Health Sci. 2016;8(5):39–47. doi: 10.5539/gjhs.v8n5p39.
    1. Sirey JA, Greenfield A, Weinberger MI, Bruce ML. Medication beliefs and self-reported adherence among community-dwelling older adults. Clin Ther. 2013;35(2):153–160. doi: 10.1016/j.clinthera.2013.01.001.
    1. Gadkari AS, McHorney CA. Unintentional non-adherence to chronic prescription medications: how unintentional is it really? BMC Health Serv Res. 2012;12:98. doi: 10.1186/1472-6963-12-98.
    1. Berglund E, Lytsy P, Westerling R. Adherence to and beliefs in lipid-lowering medical treatments: a structural equation modeling approach including the necessity-concern framework. Patient Educ Couns. 2013;91(1):105–112. doi: 10.1016/j.pec.2012.11.001.
    1. Allen LaPointe NM, Ou FS, Calvert SB, Melloni C, Stafford JA, Harding T, et al. Changes in beliefs about medications during long-term care for ischemic heart disease. Am Heart J. 2010;159(4):561–569. doi: 10.1016/j.ahj.2009.12.025.
    1. Moen J, Bohm A, Tillenius T, Antonov K, Nilsson JL, Ring L. "I don't know how many of these [medicines] are necessary.."—a focus group study among elderly users of multiple medicines. Patient Educ Couns. 2009;74(2):135–141. doi: 10.1016/j.pec.2008.08.019.
    1. Shoemaker SJ, Ramalho de Oliveira D. Understanding the meaning of medications for patients: the medication experience. Pharm World Sci. 2008;30(1):86–91. doi: 10.1007/s11096-007-9148-5.
    1. Krska J, Morecroft CW, Poole H, Rowe PH. Issues potentially affecting quality of life arising from long-term medicines use: a qualitative study. Int J Clin Pharm. 2013;35(6):1161–1169. doi: 10.1007/s11096-013-9841-5.
    1. Dunn SP, Birtcher KK, Beavers CJ, Baker WL, Brouse SD, Page RL, 2nd, et al. The role of the clinical pharmacist in the care of patients with cardiovascular disease. J Am Coll Cardiol. 2015;66(19):2129–2139. doi: 10.1016/j.jacc.2015.09.025.
    1. Clark C, Smith L, Cloutier L, Glynn L, Clark O, Taylor R, et al. LB01.01: Allied health professional-led interventions for improving control of blood pressure in patients with hypertension: a cochrane systematic review and meta-analysis. J Hypertens. 2015;33 suppl 1:e44. doi: 10.1097/01.hjh.0000467463.16386.51.
    1. Santschi V, Chiolero A, Colosimo AL, Platt RW, Taffe P, Burnier M, et al. Improving blood pressure control through pharmacist interventions: a meta-analysis of randomized controlled trials. J Am Heart Assoc. 2014;3(2):e000718. doi: 10.1161/JAHA.113.000718.
    1. Santschi V, Chiolero A, Burnand B, Colosimo AL, Paradis G. Impact of pharmacist care in the management of cardiovascular disease risk factors: a systematic review and meta-analysis of randomized trials. Arch Intern Med. 2011;171(16):1441–1453. doi: 10.1001/archinternmed.2011.399.
    1. Martínez-Mardones F, Fernandez-Llimos F, Benrimoj SI, Ahumada-Canale A, Plaza-Plaza JC, Tonin FS, et al. Systematic review and meta-analysis of medication reviews conducted by pharmacists on cardiovascular diseases risk factors in ambulatory care. J Am Heart Assoc. 2019;8(22):e013627. doi: 10.1161/JAHA.119.013627.
    1. World Health Organization . Adherence to long-term therapies—evidence for action. Geneva: World Health Organization; 2003.
    1. Zomahoun HT, Guenette L, Gregoire JP, Lauzier S, Lawani AM, Ferdynus C, et al. Effectiveness of motivational interviewing interventions on medication adherence in adults with chronic diseases: a systematic review and meta-analysis. Int J Epidemiol. 2016 doi: 10.1093/ije/dyw273.
    1. Palacio A, Garay D, Langer B, Taylor J, Wood BA, Tamariz L. Motivational interviewing improves medication adherence: a systematic review and meta-analysis. J Gen Intern Med. 2016;31(8):929–940. doi: 10.1007/s11606-016-3685-3.
    1. Easthall C, Song F, Bhattacharya D. A meta-analysis of cognitive-based behaviour change techniques as interventions to improve medication adherence. BMJ Open. 2013;3(8):e002749. doi: 10.1136/bmjopen-2013-002749.
    1. Rubak S, Sandbaek A, Lauritzen T, Borch-Johnsen K, Christensen B. Effect of "motivational interviewing" on quality of care measures in screen detected type 2 diabetes patients: a one-year follow-up of an RCT, ADDITION Denmark. Scand J Prim Health Care. 2011;29(2):92–98. doi: 10.3109/02813432.2011.554271.
    1. Ogedegbe G, Chaplin W, Schoenthaler A, Statman D, Berger D, Richardson T, et al. A practice-based trial of motivational interviewing and adherence in hypertensive African Americans. Am J Hypertens. 2008;21(10):1137–1143. doi: 10.1038/ajh.2008.240.
    1. Hedegaard U, Kjeldsen LJ, Pottegård A, Henriksen JE, Lambrechtsen J, Hangaard J, et al. Improving medication adherence in patients with hypertension: a randomized trial. Am J Med. 2015;128(12):1351–1361. doi: 10.1016/j.amjmed.2015.08.011.
    1. Al-Ganmi AH, Perry L, Gholizadeh L, Alotaibi AM. Cardiovascular medication adherence among patients with cardiac disease: a systematic review. J Adv Nurs. 2016;72(12):3001–3014. doi: 10.1111/jan.13062.
    1. Ostbring MJ, Eriksson T, Petersson G, Hellstrom L. Motivational Interviewing and Medication Review in Coronary Heart Disease (MIMeRiC): protocol for a randomized controlled trial investigating effects on clinical outcomes, adherence, and quality of life. JMIR Res Protoc. 2018;7(2):e57. doi: 10.2196/resprot.8659.
    1. Ostbring MJ, Eriksson T, Petersson G, Hellstrom L. Motivational Interviewing and Medication Review in Coronary Heart Disease (MIMeRiC): intervention development and protocol for the process evaluation. JMIR Res Protoc. 2018;7(1):e21. doi: 10.2196/resprot.8660.
    1. Griese-Mammen N, Hersberger KE, Messerli M, Leikola S, Horvat N, van Mil JWF, et al. PCNE definition of medication review: reaching agreement. Int J Clin Pharm. 2018;40(5):1199–1208. doi: 10.1007/s11096-018-0696-7.
    1. Hellstrom LM, Bondesson A, Hoglund P, Midlov P, Holmdahl L, Rickhag E, et al. Impact of the Lund Integrated Medicines Management (LIMM) model on medication appropriateness and drug-related hospital revisits. Eur J Clin Pharmacol. 2011;67(7):741–752. doi: 10.1007/s00228-010-0982-3.
    1. Hellstrom LM, Hoglund P, Bondesson A, Petersson G, Eriksson T. Clinical implementation of systematic medication reconciliation and review as part of the Lund Integrated Medicines Management model–impact on all-cause emergency department revisits. J Clin Pharm Ther. 2012;37(6):686–692. doi: 10.1111/jcpt.12001.
    1. Perk J, De-Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) Eur Heart J. 2012;33(13):1635–1701. doi: 10.1093/eurheartj/ehs092.
    1. Vrijens B, De Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppar T, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73(5):691–705. doi: 10.1111/j.1365-2125.2012.04167.x.
    1. Krousel-Wood M, Holt E, Joyce C, Ruiz R, Dornelles A, Webber LS, et al. Differences in cardiovascular disease risk when antihypertensive medication adherence is assessed by pharmacy fill versus self-report: the Cohort Study of Medication Adherence among Older Adults (CoSMO) J Hypertens. 2015;33(2):412–420. doi: 10.1097/HJH.0000000000000382.
    1. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich) 2008;10(5):348–354. doi: 10.1111/j.1751-7176.2008.07572.x.
    1. Krousel-Wood M, Islam T, Webber LS, Re RN, Morisky DE, Muntner P. New medication adherence scale versus pharmacy fill rates in seniors with hypertension. Am J Manag Care. 2009;15(1):59–66.
    1. Morisky DE, DiMatteo MR. Improving the measurement of self-reported medication nonadherence: response to authors. J Clin Epidemiol. 2011;64(3):255–257. doi: 10.1016/j.jclinepi.2010.09.002.
    1. De Vera MA, Bhole V, Burns LC, Lacaille D. Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review. Br J Clin Pharmacol. 2014;78(4):684–698. doi: 10.1111/bcp.12339.
    1. Oldridge N, Hofer S, McGee H, Conroy R, Doyle F, Saner H. The HeartQoL: Part II. Validation of a new core health-related quality of life questionnaire for patients with ischemic heart disease. Eur J Prev Cardiol. 2013;21:98–106. doi: 10.1177/2047487312450545.
    1. White IR, Carpenter J, Horton NJ. Including all individuals is not enough: lessons for intention-to-treat analysis. Clin Trials. 2012;9(4):396–407. doi: 10.1177/1740774512450098.
    1. Jakobsen JC, Gluud C, Wetterslev J, Winkel P. When and how should multiple imputation be used for handling missing data in randomised clinical trials—a practical guide with flowcharts. BMC Med Res Methodol. 2017;17(1):162. doi: 10.1186/s12874-017-0442-1.
    1. Sullivan TR, White IR, Salter AB, Ryan P, Lee KJ. Should multiple imputation be the method of choice for handling missing data in randomized trials? Stat Methods Med Res. 2018;27(9):2610–2626. doi: 10.1177/0962280216683570.
    1. White IR, Horton NJ, Carpenter J, Pocock SJ. Strategy for intention to treat analysis in randomised trials with missing outcome data. BMJ (Clin Res ed) 2011;342:d40. doi: 10.1136/bmj.d40.
    1. Enders CK. Using the expectation maximization algorithm to estimate coefficient alpha for scales with item-level missing data. Psychol Methods. 2003;8(3):322–337. doi: 10.1037/1082-989X.8.3.322.
    1. Clifford S, Barber N, Elliott R, Hartley E, Horne R. Patient-centred advice is effective in improving adherence to medicines. Pharm World Sci. 2006;28(3):165–170. doi: 10.1007/s11096-006-9026-6.
    1. Odeh M, Scullin C, Fleming G, Scott MG, Horne R, McElnay JC. Ensuring continuity of patient care across the healthcare interface: telephone follow-up post-hospitalization. Br J Clin Pharmacol. 2019;85(3):616–625. doi: 10.1111/bcp.13839.
    1. Chapman S, Sibelli A, St-Clair Jones A, Forbes A, Chater A, Horne R. Personalised adherence support for maintenance treatment of inflammatory bowel disease: a tailored digital intervention to change adherence-related beliefs and barriers. J Crohns Colitis. 2020;14(10):1394–1404. doi: 10.1093/ecco-jcc/jjz034.
    1. Hovland R, Bremer S, Frigaard C, Henjum S, Faksvåg PK, Saether EM, et al. Effect of a pharmacist-led intervention on adherence among patients with a first-time prescription for a cardiovascular medicine: a randomized controlled trial in Norwegian pharmacies. Int J Pharm Pract. 2020;28(4):337–345. doi: 10.1111/ijpp.12598.
    1. Foot H, La Caze A, Gujral G, Cottrell N. The necessity-concerns framework predicts adherence to medication in multiple illness conditions: a meta-analysis. Patient Educ Couns. 2016;99(5):706–717. doi: 10.1016/j.pec.2015.11.004.
    1. Khalaf K, Johnell K, Austin PC, Tyden P, Midlov P, Perez-Vicente R, et al. Low adherence to statin treatment during the first year after an acute myocardial infarction is associated with increased second year mortality risk—an inverse probability of treatment weighted study on 54,872 patients. Eur Heart J Cardiovasc Pharmacother. 2020;7:141–147. doi: 10.1093/ehjcvp/pvaa010.
    1. Karlsson SA, Hero C, Svensson AM, Franzen S, Miftaraj M, Gudbjornsdottir S, et al. Association between refill adherence to lipid-lowering medications and the risk of cardiovascular disease and mortality in Swedish patients with type 2 diabetes mellitus: a nationwide cohort study. BMJ Open. 2018;8(3):e020309. doi: 10.1136/bmjopen-2017-020309.
    1. Hedegaard U, Kjeldsen LJ, Pottegård A, Bak S, Hallas J. Multifaceted intervention including motivational interviewing to support medication adherence after stroke/transient ischemic attack: a randomized trial. Cerebrovasc Dis Extra. 2014;4(3):221–234. doi: 10.1159/000369380.
    1. Lin CY, Yaseri M, Pakpour AH, Malm D, Brostrom A, Fridlund B, et al. Can a multifaceted intervention including motivational interviewing improve medication adherence, quality of life, and mortality rates in older patients undergoing coronary artery bypass surgery? a multicenter, randomized controlled trial with 18-month follow-up. Drugs Aging. 2017;34(2):143–156. doi: 10.1007/s40266-016-0429-3.
    1. Ho PM, Lambert-Kerzner A, Carey EP, Fahdi IE, Bryson CL, Melnyk SD, et al. Multifaceted intervention to improve medication adherence and secondary prevention measures after acute coronary syndrome hospital discharge: a randomized clinical trial. JAMA Intern Med. 2014;174(2):186-93.
    1. Choudhry NK, Avorn J, Glynn RJ, Antman EM, Schneeweiss S, Toscano M, et al. Full coverage for preventive medications after myocardial infarction. N Engl J Med. 2011;365(22):2088–2097. doi: 10.1056/NEJMsa1107913.
    1. Authors/Task Force M, Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, et al. European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR) Atherosclerosis. 2016;2016(252):207–274.
    1. Stone NJ, Robinson JG, Lichtenstein AH, Goff DC, Jr, Lloyd-Jones DM, Smith SC, Jr, et al. Treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: synopsis of the 2013 American College of Cardiology/American Heart Association cholesterol guideline. Ann Intern Med. 2014;160(5):339–343. doi: 10.7326/M14-0126.
    1. Sundstrom J, Hedberg J, Thuresson M, Aarskog P, Johannesen KM, Oldgren J. Low-dose aspirin discontinuation and risk of cardiovascular events: a Swedish Nationwide. Popul Based Cohort Study Circ. 2017;136(13):1183–1192.
    1. Ho PM, Spertus JA, Masoudi FA, Reid KJ, Peterson ED, Magid DJ, et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med. 2006;166(17):1842–1847. doi: 10.1001/archinte.166.17.1842.
    1. Nieuwlaat R, Wilczynski N, Navarro T, Hobson N, Jeffery R, Keepanasseril A, et al. Interventions for enhancing medication adherence. Cochrane Database of Syst Rev. 2014;2014(11):cd000011.
    1. Gianos E, Schoenthaler A, Guo Y, Zhong J, Weintraub H, Schwartzbard A, et al. Investigation of motivational interviewing and prevention consults to achieve cardiovascular targets (IMPACT) trial. Am Heart J. 2018;199:37–43. doi: 10.1016/j.ahj.2017.12.019.
    1. Sieben A, van Onzenoort HA, van Dulmen S, van Laarhoven C, Bredie SJ. A nurse-based intervention for improving medication adherence in cardiovascular patients: an evaluation of a randomized controlled trial. Patient Prefer Adherence. 2019;13:837–852. doi: 10.2147/PPA.S197481.
    1. Ivers NM, Schwalm JD, Bouck Z, McCready T, Taljaard M, Grace SL, et al. Interventions supporting long term adherence and decreasing cardiovascular events after myocardial infarction (ISLAND): pragmatic randomised controlled trial. BMJ (Clin Res Ed) 2020;369:m1731.
    1. Conn VS, Ruppar TM. Medication adherence outcomes of 771 intervention trials: systematic review and meta-analysis. Prev Med. 2017;99:269–276. doi: 10.1016/j.ypmed.2017.03.008.
    1. Cutrona SL, Choudhry NK, Stedman M, Servi A, Liberman JN, Brennan T, et al. Physician effectiveness in interventions to improve cardiovascular medication adherence: a systematic review. J Gen Intern Med. 2010;25(10):1090–1096. doi: 10.1007/s11606-010-1387-9.
    1. Chase JA, Bogener JL, Ruppar TM, Conn VS. The effectiveness of medication adherence interventions among patients with coronary artery disease: a meta-analysis. J Cardiovasc Nurs. 2016;31(4):357–366. doi: 10.1097/JCN.0000000000000259.
    1. Crawshaw J, Auyeung V, Ashworth L, Norton S, Weinman J. Healthcare provider-led interventions to support medication adherence following ACS: a meta-analysis. Open Heart. 2017;4(2):e000685.
    1. Huber D, Henriksson R, Jakobsson S, Mooe T. Nurse-led telephone-based follow-up of secondary prevention after acute coronary syndrome: One-year results from the randomized controlled NAILED-ACS trial. PLoS ONE. 2017;12(9):e0183963. doi: 10.1371/journal.pone.0183963.
    1. Daniel H, Christian W, Robin H, Lars S, Thomas M. Statin treatment after acute coronary syndrome: adherence and reasons for non-adherence in a randomized controlled intervention trial. Sci Rep. 2019;9(1):12079. doi: 10.1038/s41598-019-48540-3.
    1. Wiecek E, Tonin FS, Torres-Robles A, Benrimoj SI, Fernandez-Llimos F, Garcia-Cardenas V. Temporal effectiveness of interventions to improve medication adherence: a network meta-analysis. PLoS ONE. 2019;14(3):e0213432. doi: 10.1371/journal.pone.0213432.
    1. Bernal DD, Bereznicki LR, Chalmers L, Castelino RL, Thompson A, Davidson PM, et al. Medication adherence following acute coronary syndrome: does one size fit all? Am J Cardiovasc Drugs Drugs Dev Other Interv. 2016;16(1):9–17. doi: 10.1007/s40256-015-0149-9.
    1. Bosworth HB, Blalock DV, Hoyle RH, Czajkowski SM, Voils CI. The role of psychological science in efforts to improve cardiovascular medication adherence. Am Psychol. 2018;73(8):968–980. doi: 10.1037/amp0000316.
    1. Sieben A, Bredie SJH, Luijten J, van Laarhoven C, van Dulmen S, van Onzenoort HAW. Prior medication adherence of participants and non participants of a randomized controlled trial to improve patient adherence in cardiovascular risk management. BMC Med Res Methodol. 2019;19(1):95. doi: 10.1186/s12874-019-0743-7.
    1. Crawshaw J, Auyeung V, Norton S, Weinman J. Identifying psychosocial predictors of medication non-adherence following acute coronary syndrome: a systematic review and meta-analysis. J Psychosom Res. 2016;90:10–32. doi: 10.1016/j.jpsychores.2016.09.003.
    1. Axelsson M, Brink E, Lundgren J, Lotvall J. The influence of personality traits on reported adherence to medication in individuals with chronic disease: an epidemiological study in West Sweden. PLoS ONE. 2011;6(3):e18241. doi: 10.1371/journal.pone.0018241.
    1. Jerant A, Chapman B, Duberstein P, Robbins J, Franks P. Personality and medication non-adherence among older adults enrolled in a six-year trial. Br J Health Psychol. 2011;16(Pt 1):151–169. doi: 10.1348/135910710X524219.
    1. Östbring MJ, Hellström L, Mårtensson J. Trivial or troublesome: experience with coronary heart disease medication from the patient's perspective. Patient Prefer Adherence. 2020;14:411–424. doi: 10.2147/PPA.S230120.
    1. van der Laan DM, Elders PJM, Boons C, Nijpels G, Krska J, Hugtenburg JG. The impact of cardiovascular medication use on patients' daily lives: a cross-sectional study. Int J Clin Pharm. 2018;40(2):412–420. doi: 10.1007/s11096-018-0601-4.
    1. Krska J, Corlett SA, Katusiime B. Complexity of medicine regimens and patient perception of medicine burden. Pharmacy (Basel, Switzerland). 2019;7(1):18.
    1. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH) Eur Heart J. 2018;39(33):3021–3104. doi: 10.1093/eurheartj/ehy339.
    1. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Eur Heart J. 2019;41(1):111–188. doi: 10.1093/eurheartj/ehz455.
    1. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD) Eur Heart J. 2019;41(2):255–323. doi: 10.1093/eurheartj/ehz486.
    1. Hillman LA, Peden-McAlpine C, Ramalho-de-Oliveira D, Schommer JC. The medication experience: a concept analysis. Pharmacy (Basel, Switzerland). 2020;9(1):7.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner